As for safety, experts interviewed for this story said they are extremely confident in the systems set up to monitor vaccine ...

The move comes as GSK faces pressure to replenish its pipeline, with some of its top-selling drugs nearing the end of their ...

British pharmaceutical giant GlaxoSmithKline announced Wednesday the acquisition of a drug under development to treat a ...

The company registered standalone net profits after tax of EGP 43.559 million in Q1 2025, compared to EGP 2.046 million in net losses during Q1 2024 ...

Todays focus will be on GSK Pharma shares in light of the companys announced topline growth and profitability for the full ...

Decision follows underwhelming Phase II results from GALAXIES Lung-201 and H&N-202 trials, prompting iTeos and GSK to end ...

Teos Therapeutics downgraded to Hold after belrestotug failure and GSK deal ending. Read my updated analysis on ITOS stock ...

GSK will buy efimosfermin, a liver disease drug in late-stage trials, for up to $2 billion from U.S. biotechnology firm ...

Andrew Witty is stepping down for "personal reasons" while the Minnesota-based insurer suspends its full-year financial ...

Mucus plugs affect some 40% to nearly 70% of COPD patients, and even clinically silent mucus plugs are linked to poorer ...

Andrew Witty is a business executive well-known for his contributions to the Pharmaceutical and health sectors.

O-I Glass, Inc. (“O-I” or the “Company”) (NYSE: OI) today announced, after the conclusion of O-I’s Annual Meeting of Share ...